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ABSTRACT 
Parasitic diseases, such as African sleeping sickness, have a significant impact on the health and well-being in the poorest regions of the world. 
Pragmatic drug discovery efforts are needed to find new therapeutic agents. In this report we describe target repurposing efforts focused on 
trypanosomal phosphodiesterases. We outline the synthesis and biological evaluation of analogs of sildenafil (1), a human PDE5 inhibitor, for activities 
against trypanosomal PDEB1 (TbrPDEB1). We find that, while low potency analogs can be prepared, this chemical class is a sub-optimal starting point 
for further development of TbrPDE inhibitors. 
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Tropical diseases such as human African trypanosomiasis (HAT), leishmaniasis, and Chagas’ disease are often referred to as 
“neglected” diseases, as the low level of funding of drug discovery research is disproportionate to the total disease burden. For example, 
collectively these three diseases endanger over 73 million people globally1 and create a burden of 4.5 million disability-adjusted life-
years.2,3 Yet, few compounds have advanced to clinical studies for these diseases.4 The primary reason for this disparity is the high cost 
of drug discovery and unlikelihood that these research costs will be recouped by a research organization via drug sales to highly 
impoverished populations.  
As a result, cost-effective methods for identification of lead matter and expediting compound optimization efforts are acutely 
needed. We apply the method of “target repurposing”, wherein essential parasite enzymes are matched with proven, druggable human 
homologs.4 By doing so, the research outputs of large and expensive programs of historical drug discovery projects can be used to 
initiate and drive optimization projects against parasitic targets.  
Phosphodiesterases (PDEs) are a family of enzymes that maintain the balance of cAMP and cGMP in the cell, opposed to adenylate 
and guanylate cyclase, respectively. Humans possess eleven PDEs, several of which have been fruitfully pursued for drug discovery. 
The most well-known of these is PDE5, an enzyme that is inhibited by erectile dysfunction drugs such as Viagra™ (sildenafil, 1), 
Cialis™ (tadalafil, 2), and Levitra™ (vardenafil, 3), Figure 1. Other PDEs are of demonstrated relevance to inflammatory conditions 
and CNS indications, such as schizophrenia.5-7 Trypanosoma brucei, the causative agent of HAT, expresses five cAMP-specific PDEs,8 
two of which (TbrPDEB1 and TbrPDEB2) have together been shown by both RNAi9,10 and small molecules10,11 to be essential for 
parasite proliferation. While initial benchmarking and early optimization experiments have uncovered a susceptibility of TbrPDEB1 and 
B2 to human PDE4 inhibitors,11 the two trypanosomal enzymes are also 31% identical to PDE5 within their respective catalytic 
domains, and previous reports cited low potency of 1 and 2 against the trypanosomal enzymes; thus, we describe here early structure-
activity relationships (SAR) of (1), and report such work for 2 in a subsequent article.12 
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Figure 1. Human PDE5 inhibitors marketed for erectile dysfunction. 
 
We initially tested 1 for its inhibitory activity against the catalytic domain of TbrPDEB1, and observed low potency (51% at 100 
µM). However, we deemed this chemotype worth further exploration given the extensive knowledge of SAR and structural biology 
around it. We performed activity scoping experiments by making strategic changes to the structure of 1, to explore the impact of 
variation of the N-methyl group and propyl chain on the pyrazolopyrimidinone core (Region A), and of the specific functionality on 
Region B. We were particularly interested in exploring the western portion of 1, as this region of the molecule was proposed to project 
into a parasite-specific pocket (the P-pocket). This pocket was first observed in the Leishmania major phosphodiesterase LmjPDEB113 
and is predicted to also exist in TbrPDEB1,11 but, importantly, is absent from all human PDEs.  
Keywords: 
HN
N
N
N
O
O
O2S N
N
Region A
Region B
"P-pocket" 1
 
Figure 2. Strategy for exploration of the sildenafil core. 
 
Compounds that explore Regions A and B were synthesized using the routes outlined in Schemes 1 and 2. The known 
aminopyrazole  4a14 or 4b15 was acylated with the appropriate benzoic acid and cyclized under basic conditions to give  5-10. Pyrazole 
N-arylation was achieved using copper catalysis16 to prepare 11-13. Alkylation of 7 with bromoacetamide provided 14. 
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Scheme 1. Synthesis of 5-14. Reagents and Conditions. (a) PyBroP, TEA, DCE, 120 oC, MW, 10 min; (b) NH4OH, dioxane, rt; (c) NaOEt/EtOH, 120 oC, 
MW, 10 min; (d) R1-I, CuI, trans-cyclohexane-1,2-diamine, Cs2CO3,DMF, 110 oC;  (e) NaH, 2-bromoacetamide, 0 oC to rt.  Refer to Table 1 for the identity of R-
groups. 
The preparation of Strategy B analogs of compound 1 is illustrated in Scheme 2. The appropriate aminopyrazole 15,17 16,18 or 1719 is 
acylated with A using either CDI or PyBroP; these reaction conditions surprisingly resulted in the partial-to-complete hydrolysis of the 
primary amide (of 14 and 15) or ester (of 16). Thus, the resulting carboxylic acid 18 was converted to the primary amide 19 via 
treatment with thionyl chloride, followed by ammonia in isopropanol. Cyclization to the desired products was effected under basic 
conditions. 
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Scheme 2. Synthesis of 20-22. Reagents and Conditions.(a) CDI, A,70 oC, EtOAc, o/n;  (b) PyBroP, A, Et3N, DCE, MW 120 oC 20 min; (c) SOCl2; (d) NH3, 
iPrOH; (e) NaOEt, EtOH, MW 120 oC 10 min. 
Following synthesis, the analogs were tested in biochemical assays11 at a single concentration. Notably, with one exception (7), none 
of the analogs that varied the pyrazole N1 substituent (H, Me, 3-pyridyl, or acetamide) nor the C3 position (H, Me, Pr, Ph) showed 
improved potency over 1.  
Table 1. Results of biochemical screening of analogs of 1. 
Entry Compd R1 R2 R3 R4 TbrPDEB1 
(%inh)a 
1 1 CH3 Pr OEt 
N
N
S
O
O
 
51.5 
2 7 H Ph OEt  70.9  
3 13 3-Pyr Pr OEt  32.4 
4 22 CH3 Ph OEt  17.5 
5 10 H Pr OEt  16.0 
6 20 CH3 H OEt  13.6 
7 8 CH3 Pr H  8.4 
8 21 CH3 CH3 OEt  NDb 
9 6 H Ph OEt H 22.9  
10 9 CH3 Pr OEt H 21.8  
11 14 CH2CONH2 Ph OEt H 7 
12 11 Ph Ph OEt H NDb 
13 12 3-Pyr Ph OEt H NDb 
14 5 H Pr OEt H NDb 
aStandard assay conditions: 100µM, 10% DMSO. cCompound showed lack of solubility, which precluded testing. 
The removal of the N-methylpiperazinyl sulfonamide head group resulted in compounds with significant loss in solubility, and as 
such biochemical screening data was not possible with some analogs (Table 1, entries 8, 12-14). 
A broad exploration of heterocyclic substitutions in Region B was undertaken by application of parallel synthesis (Scheme 3). This 
was achieved by condensing the commercially available pyrazole amino amide 23 with various monocyclic heteroaromatic carboxylic 
acids that were available in pre-weighed quantities from a commercial vendor (ASDI, Inc). Following this amidation reaction, 
cyclization was achieved by treatment with sodium ethoxide in ethanol.  
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Scheme 3. Synthesis of  24a-d. Reagents and Conditions. (a) R5CO2H, imidazole-HCl, CDI, then 23, 50 oC, o/n; . b) EtOH, NaOEt, 120 oC, 2 h. Refer to 
Table 2 for the identity of R-groups. 
 
A series of 2-alkoxy-3-pyridyl variations were prepared as shown in Scheme 4. The acylated aminopyrazole 25 was cyclized under 
basic conditions, using an appropriate alcoholic solvent, which yielded the 2-alkoxypyridyl derivatives 26. 
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Scheme 4. Synthesis of  26a-c. Reagents and Conditions. a) 2-chloronicotinic acid, PyBroP, Et3N; (b) R-OH, KOtBu.  
 
Table 2 summarizes the biochemical results for analogs prepared using this parallel methodology that display >25% inhibition at 100 
µM (characterization and biochemical data for all compounds are listed in the Supporting Information). In brief, heterocycles show 
improved potency at TbrPDEB1, specifically, 2-methoxy-3-pyridyl and 3-methyl-2-pyridyl show the best potency (entries 1-2); larger 
2-alkoxy groups (entries  3 and 4) lead to reduced activity. Unfortunately, dose-response experiments with 26c were precluded by poor 
solubility at higher concentrations. 
Table 2. Analogs of sildenafil (Strategy A). 
# 
Compound R5 
TbrPDEB1 
(%inh)a 
1 26c 2-methoxy-3-pyridyl 77.2 
2 24a 3-methyl-2-pyridyl 72.1 
3 26a 2-isopropoxy-3-pyridyl  53.8 
4 26b 2-ethoxy-3-pyridyl  41.5 
5 24b 2-methyl-5-pyrazinyl 30.0 
6 24c 2,4-dimethyloxazol-5-yl 29.0 
7 24d thiazol-4-yl 25.4 
aStandard assay conditions: 100µM, 10% DMSO  
 
While we appreciate that the potencies of the compounds shown in Tables 1 and 2 are modest, it is clear that 7, 26c and 24a 
represent qualitative potency improvement over 1. Nonetheless, the current exploration of the various regions of the sildenafil template 
is not suggestive of promising structure-activity relationship trends.  
In conclusion, with the broad interest in repurposing PDE inhibitors for neglected diseases11,20,21 and the extensive precedent in 
medicinal chemistry for human PDE5 inhibitors, we note our finding that these initial sildenafil analogs do not represent as strong 
starting points for further optimization for TbrPDEB inhibition as the PDE4 chemotypes previously reported.11 This information may be 
deemed important for re-prioritizing the focus of these efforts.  
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